文献速递淋巴瘤

ALK阴性间变性大细胞淋巴瘤:国际T细胞项目235例患者的特征与结局

ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project.
PubMed 文献 · Blood Adv · 2021-01-01

国际T细胞项目是一项全球前瞻性队列研究,2006年9月至2018年2月共纳入1553例外周T细胞淋巴瘤患者,其中235例为ALK阴性间变性大细胞淋巴瘤。中位随访52个月,中位无进展生存期41个月,中位总生存期55个月,3年和5年总生存率分别为60%和49%。含蒽环类和依托泊苷的治疗方案与更优总生存相关。

要点

  • ALK阴性ALCL诊断时中位年龄54岁,62%为男性,71%为III-IV期。
  • 初始总缓解率77%,完全缓解率63%,中位PFS 41个月,中位OS 55个月。

核心结论

  • 该大型前瞻性队列中ALK阴性ALCL的结局与既往回顾性国际外周T细胞淋巴瘤项目报道相当。
  • 研究强调需要为ALK阴性ALCL引入新的治疗平台,并为未来临床试验建立基准。

研究设计与样本

  • 国际T细胞项目是一项全球前瞻性队列研究,通过集中计算机数据库连续入组新诊断外周T细胞淋巴瘤患者。
  • 2006年9月至2018年2月,来自全球13个国家74个中心的1553例 validated 病例中,235例报告为ALK阴性ALCL。

主要发现

  • 诊断时中位年龄54岁(范围18-89岁),男性占62%,III-IV期占71%,大肿块和骨髓受累不常见。
  • 66%的患者国际预后指数评分为低危(0-1分)。
  • 所有接受治疗的患者中,85%接受多药初始化疗,8%接受自体造血干细胞移植巩固。
  • 初始总缓解率和完全缓解率分别为77%和63%。
  • 中位随访52个月(95%CI 41-63),中位PFS为41个月(95%CI 17-62),中位OS为55个月(95%CI 36-75)。

关键数值与推荐

  • 3年和5年PFS率分别为52%和43%。
  • 3年和5年OS率分别为60%和49%。

临床怎么用

  • ALK阴性ALCL常表现为晚期疾病但骨髓和大肿块受累不常见,多数患者IPI为低危。
  • 多药化疗可获得较高缓解率,但长期生存仍不理想,含蒽环类和依托泊苷方案可能与更优OS相关。

局限性

  • 原文未报告具体局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anaplastic lymphoma kinase-negative anaplastic large cell lymphoma (ALK- ALCL) is an aggressive neoplasm of T-cell/null-cell lineage. The T-Cell Project is a global prospective cohort study that consecutively enrolled patients newly diagnosed with peripheral T-cell lymphoma, registered through a centralized computer database between September 2006 and February 2018. Of 1553 validated cases from 74 sites in 13 countries worldwide, 235 were reported as ALK- ALCL. The median age at diagnosis was 54 years (range, 18-89 years), with a male predominance (62%). Stage III to IV disease was identified in 71% of patients, bulky disease and bone marrow involvement were uncommon, and 66% of patients presented with a low (0-1) International Prognostic Index score. Of all treated patients, 85% received multiagent initial chemotherapy, and 8% were consolidated with autologous hematopoietic cell transplantation. The initial overall and complete response rates were 77% and 63%, respectively. After a median follow-up of 52 months (95% confidence interval [CI], 41-63), the median progression-free survival (PFS) and overall survival (OS) were 41 months (95% CI, 17-62) and 55 months (95% CI, 36-75), respectively. The 3- and 5-year PFS rates were 52% and 43%, and the 3- and 5-year OS rates were 60% and 49%. Treatments containing both anthracycline and etoposide were associated with superior OS (P = .05) but not PFS (P = .18). In this large prospective cohort study, outcomes comparable to those previously reported in the retrospective International Peripheral T-Cell Lymphoma Project were observed. The study underscores the need for introducing novel platforms for ALK- ALCL and establishes a benchmark for future clinical trials. This trial was registered at www.clinicaltrials.gov as #NCT01142674.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Shustov A, Cabrera ME, Civallero M, et al. ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. Blood Adv. 2021. PMID: 33560375. doi:10.1182/bloodadvances.2020001581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。